Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,386 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Pathologies Clear all
Completed Phase 2 Interventional

Peginesatide for Anemia in Chronic Hemodialysis Patients

NCT00228449
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370538
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Mobile, Alabama • San Francisco, California • Westlake Village, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Nov 6, 2026, 4:38 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

NCT06721871
View directory record Official record
Conditions
Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
Interventions
Crofelemer Powder for Oral Solution, Placebo Powder for Oral Solution
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 1 Interventional Results available

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

NCT01949532
View directory record Official record
Conditions
Relapsed Multiple Myeloma, End-stage Renal Disease
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Detroit, Michigan • Lake Success, New York • Canton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.

NCT00801398
View directory record Official record
Conditions
Postoperative Pain
Interventions
Oxymorphone IR
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Nov 6, 2026, 4:38 PM EST
Terminated No phase listed Observational

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

NCT04827563
View directory record Official record
Conditions
Multiple Myeloma, Shortness of Breath, Dyspnea, Cardiotoxicity
Interventions
EndoPAT, Blood Pressure Cuff, Echocardiogram, Quality of Life Assessment, Blood Tests
Device · Diagnostic Test · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 6, 2026, 4:38 PM EST
Completed No phase listed Observational

Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant

NCT00281814
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Nov 6, 2026, 4:38 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive BCI-controlled Assistive Devices

NCT05183152
View directory record Official record
Conditions
Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
Interventions
NMES Feedback, Visual Feedback, TESS
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 6, 2026, 4:38 PM EST
Completed Not applicable Interventional

Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)

NCT00594087
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders, Fatigue
Interventions
eszopiclone, placebo
Drug · Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 5, 2009 · Synced Nov 6, 2026, 4:38 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

NCT04883593
View directory record Official record
Conditions
Tinea Pedis
Interventions
TA103, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 3 Interventional Results available

Acute Renal Failure Trial Network (ATN) Study

NCT00076219
View directory record Official record
Conditions
Acute Renal Failure
Interventions
renal replacement therapy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
22
States / cities
No. Little Rock, Arkansas • San Francisco, California • West Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

NCT04838639
View directory record Official record
Conditions
Obesity
Interventions
NO-13065, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Nov 6, 2026, 4:38 PM EST
Completed Not applicable Interventional

Self-Management Interventions Using Mobile Health for the Multimorbid

NCT04566107
View directory record Official record
Conditions
Multiple Chronic Conditions
Interventions
mHealth intervention, mHealth Plus
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Nov 6, 2026, 4:38 PM EST
Not listed Phase 2 Interventional

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

NCT00008307
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study

NCT03832192
View directory record Official record
Conditions
Delirium, Fall Injury
Interventions
care.coach Avatar (HELP-Protocolized)
Behavioral
Lead sponsor
Victor Wang
Industry
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 6, 2026, 4:38 PM EST
Recruiting Phase 3 Interventional

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions
AP301, AP301 Low Dose
Drug
Lead sponsor
Alebund Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 6, 2026, 4:38 PM EST
Recruiting Not applicable Interventional

The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease

NCT04505865
View directory record Official record
Conditions
Atherosclerosis, Stress, Inflammation
Interventions
Stress Reduction
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 6, 2026, 4:38 PM EST
Terminated No phase listed Observational

Studying Fentanyl in Patients With Cancer

NCT00899951
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fentanyl citrate, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Nov 6, 2026, 4:38 PM EST
Terminated No phase listed Observational

Incisional Hernia Outcomes Study Using Parietex Composite Mesh

NCT00459602
View directory record Official record
Conditions
Incisional Hernia
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

NCT03824912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Long Beach, California • Miami, Florida • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Nov 6, 2026, 4:38 PM EST
Recruiting Phase 3 Interventional

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Orelabrutinib, Placebo
Drug
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 4:38 PM EST
Completed Not applicable Interventional Results available

Active Bathing to Eliminate Infection (ABATE Infection) Trial

NCT02063867
View directory record Official record
Conditions
Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms
Interventions
Arm 2: Decolonization
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
52
States / cities
West Hills, California • Thornton, Colorado • Bradenton, Florida + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Nov 6, 2026, 4:38 PM EST
Completed Phase 2 Interventional

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

NCT00110799
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
Interventions
SB497115, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Nov 6, 2026, 4:38 PM EST